Alterity Therapeutics (ASX:ATH) has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as the company prepares to advance its lead therapy into a pivotal late-stage clinical trial.

Australian biotechnology company AdAlta (ASX:1AD) has expanded the clinical advisory board of its subsidiary AdCella as it prepares to advance a promising new CAR-T cell therapy for solid cancers into further development and clinical testing.

Island Pharmaceuticals (ASX:ILA) has strengthened its position in the United States biodefence research network through a new collaborative agreement aimed at accelerating the development of its antiviral drug candidate, Galidesivir, for the treatment of Marburg virus disease.

Neuren Pharmaceuticals (ASX:NEU) has moved swiftly to reinforce its confidence in DAYBUE's (trofinetide) prospects in Europe, formally backing its partner Acadia Pharmaceuticals’ plan to seek a re-examination of a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Avecho Biotechnology (ASX:AVE) has reached a critical moment in its bid to bring an over-the-counter cannabidiol treatment for insomnia to market, announcing that it has completed recruitment for the interim analysis cohort of its pivotal Phase 3 clinical trial.

An Australian research team has uncovered what could become the first new natural anti-inflammatory therapy in more than half a century, raising hopes for a significant reduction in deaths from sepsis, one of the world’s leading causes of mortality.

Entropy Neurodynamics (ASX:ENP) has completed enrolment of the first cohort in its clinical trial of TRP 8803, an intravenously infused formulation of psilocin, marking a key operational milestone in the company’s push to develop new treatments for binge eating disorder.

Botanix Pharmaceuticals (ASX:BOT) has entered 2026 with strong commercial momentum, reporting rapid growth in prescriptions and revenue for Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, while positioning the company for improved margins and platform expansion

A new Australian study suggests that a simple blood test could help doctors better identify which head and neck cancer patients are most likely to experience a relapse after treatment.

Australian company Vaxxas has been selected as part of an international consortium to help strengthen Europe’s preparedness for future seasonal and pandemic influenza threats, securing a place in a competitive European Union tender that could unlock up to $250 million in development funding.

CLINUVEL Pharmaceuticals (ASX:CUV) has reported its strongest December half-year revenue on record, underscoring what it describes as the resilience of its commercial platform and the disciplined execution of its long-term growth strategy.

Immutep (ASX:IMM) is entering an important phase of its development journey, as rising research spending and expanding clinical trials are reshaping both its financial results and its strategic outlook.

Neurizon Therapeutics (ASX:NUZ) has entered the second half of financial year 2026 in an acceleration phase, advancing its lead drug candidate while strengthening the financial and strategic foundations needed to bring it into late-stage development.

Acrux has returned to profitability for the first half of the 2026 financial year, reporting a significant improvement in performance as recently launched products delivered their first full revenue period.

Imugene (ASX:IMU) has reported a half-year shaped by tighter spending, renewed strategic focus and advancing clinical progress, as the company works to position its lead cell therapy program for the next stage of development.

The initiative is calling for expressions of interest from Australian small and medium enterprises, including start-ups and research spin-offs, that are developing medical devices to prevent, diagnose, treat, or manage heart disease and complications linked to both type 1 and type 2 diabetes.

Radiopharm Theranostics (ASX:RAD) has entered a significant new phase in its oncology program, announcing that the first patient has been dosed in a First-In-Human Phase 1/2a clinical trial of its experimental radiotherapeutic candidate, 177Lu BetaBart, also known as RV-01.